The most groundbreaking individual studies from the latest supplement and nutrition research — in plain language, with the evidence caveats built in. Research signals worth knowing about, not health advice.
This is the first systematic review to look at diet and temporomandibular disorder, but with just one small trial on vitamin D, the evidence is too thin to draw any conclusion — treat this as an early signal, not a settled answer.
This is among the first studies to flag a specific role for tocotrienols in brain structure, but because it's a scoping review of heterogeneous studies, it's a signal, not a conclusion.
This is one of the first comprehensive looks at the question, so the null result challenges the popular idea that vitamin D protects against melanoma, but the limited quality of the underlying studies means we can't rule out a real effect — the picture is now contested, not closed.
This is the first moderately strong evidence that taurine might improve blood sugar control, but it comes entirely from people recovering from COVID-19, and the underlying studies disagreed on how much it helped — so treat it as an early signal, not a settled fact.
This is a promising signal for a specific, high-risk group, but the finding comes from only a handful of studies and needs replication before it changes practice.
This is among the first large-scale analyses to test the link between high iodine and thyroid nodules, and the null result means the picture is still contested — don't treat this as settled evidence either way.
This large, long-term RCT challenges the common assumption that high-dose vitamin D prevents falls, but it's one study — the overall body of evidence on this specific pairing is still thin, so the picture isn't settled.
This is an early finding from a meta-analysis, so the picture is far from settled — but it suggests that while iodine helps correct thyroid function in deficient mothers, it might also trigger a temporary gland enlargement in specific subgroups, leaving a nuance worth watching as more evidence accumulates.
This null result questions a popular assumption, but because it's among the first studies on this specific pairing and relied on genetic proxies rather than supplementation, it does not settle the question – treat it as a cautious first look, not a final answer.
This is the first solid data linking vitamin C to a specific lung complication in premature babies, but with only 538 infants and no neurodevelopmental benefit seen, it's too early to recommend supplementation based on this result alone.
This is among the first indexed reviews on riboflavin for neurological disorders, so the finding is novel but preliminary: the apparent benefit for stroke and perinatal asphyxia rests on small studies and needs replication before it changes practice.
This is the first controlled trial to link whey protein to stronger breathing muscles in the elderly, and the effect was statistically robust — but until other labs confirm it in broader populations, treat it as an intriguing lead, not a settled fact.
This challenges the common belief that calcium supplements alone are enough to ward off low blood calcium after thyroid surgery, but the result is specific to a clinical population and the evidence base is still thin — one review doesn't settle the picture.
This contradicts the common belief that vitamin E reliably boosts male fertility after varicocele repair, but the evidence is still thin — only two randomized trials were pooled, and the result is a null finding, not a definitive refutation.
This is an early, provisional finding — the first indexed meta-analysis on this specific question — so it introduces a genuine contradiction with the idea that 'zinc works' regardless of how you take it, but the picture is too sparse to treat it as settled.
This is the first controlled human trial to suggest curcuminoids might cool a specific vasomotor symptom, but with only 40 participants and zero effect on broader menopause quality-of-life scales, it's a promising lead — not a practical recommendation yet.
This is among the first rigorous tests of pomegranate extract for inflammation in older adults, and while the results are promising for IL-6 and IL-1β, the fact that C-reactive protein and TNF-α didn’t move means the anti-inflammatory effect may be selective — and we need replication before drawing broad conclusions.
This is an intriguing early signal from a single trial in a specific clinical population, but with so little prior data, it's too soon to treat blood orange (or lycopene) as a proven preventive — the finding needs replication before it becomes actionable.
This large effect comes from a single meta-analysis within a broader umbrella review, and because this is among the first indexed studies on this specific outcome, the result is promising but still preliminary.
This systematic review is the first solid evidence linking vitamin B3 (nicotinamide) to fewer skin cancers, but with only two trials behind it, the finding is promising yet far from settled — especially since the exact dose that works remains unclear.
This review challenges the popular idea that stacking beta-alanine with creatine boosts performance further, but because it’s among the first to analyze this specific pairing, the picture isn’t settled — especially since beta-alanine may still help in narrow, task-specific scenarios not captured here.
This is the first randomized controlled trial to show that turmeric can lower thioredoxin-binding protein-2 (TBP2) and a key inflammatory driver (NF-κB) in people with type 2 diabetes. Because it’s a single study in a clinical population with undisclosed funding, the results are a promising lead — not a settled recommendation.
This is the first broad synthesis to look specifically at vitamin C plus thiamine combinations in sepsis, and the null result means the routine use of this pairing is not supported by current evidence — but because this is an early umbrella review, the picture could shift with better-designed trials.
This is a large effect on symptom severity, but it comes from early-stage, likely unblinded studies, and the benefit does not extend to preventing radiation injury from happening in the first place — so the practical takeaway is narrower than the headline number suggests.
This is the first solid randomized evidence that crocin, a compound from gardenia, might protect the heart during anthracycline chemotherapy, but it’s a single early study in a very specific clinical population — so the finding needs replication before you can trust it for anyone else.
This review challenges the popular belief that turmeric helps muscle recovery, but the evidence is still too sparse and low-quality to draw firm conclusions—especially since this is among the first indexed reviews on the topic.
This single, well-designed trial contradicts the popular idea that high-dose vitamin C is universally protective, but the evidence base is still very weak — only one of four studies on organ dysfunction showed harm, and the rest found no effect, so the picture is far from settled.
This adds to a moderate body of evidence (8 of 9 studies show benefit) that lavender can reduce anxiety, but the effect is seen here in a specific clinical population, and the same study found no improvement in depression or cognitive function — so the benefit is narrower than the headline might suggest.
This is promising early data that ginseng may modestly improve how well blood vessels dilate, but with just one small meta-analysis on this specific question, the finding needs replication before it can be treated as reliable.
This is one of the first indexed reviews to specifically test polyphenols for MS, and it found no signal for EGCG on MRI changes, disability scores, or relapse rates. But the studies it pooled were small and had methodological flaws, so the result is preliminary, not definitive.